CN104876927B - 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 - Google Patents

用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 Download PDF

Info

Publication number
CN104876927B
CN104876927B CN201510165051.4A CN201510165051A CN104876927B CN 104876927 B CN104876927 B CN 104876927B CN 201510165051 A CN201510165051 A CN 201510165051A CN 104876927 B CN104876927 B CN 104876927B
Authority
CN
China
Prior art keywords
methyl
sulfonyl
pyridin
pyrrolo
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510165051.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104876927A (zh
Inventor
M.布伦科
丁宏
G.多赫蒂
S.埃尔莫尔
L.哈斯沃尔德
L.赫克萨尔默
A.R.昆策
宋晓宏
A.J.索尔斯
G.萨利文
陶志福
G.T.王
王乐
王锡禄
M.温德特
R.曼泰
T.M.汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aibo Wei Ireland Ltd
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42677657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104876927(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN104876927A publication Critical patent/CN104876927A/zh
Application granted granted Critical
Publication of CN104876927B publication Critical patent/CN104876927B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
CN201510165051.4A 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 Active CN104876927B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18120309P 2009-05-26 2009-05-26
US61/181203 2009-05-26
CN201080023068.1A CN102448959B (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080023068.1A Division CN102448959B (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂

Publications (2)

Publication Number Publication Date
CN104876927A CN104876927A (zh) 2015-09-02
CN104876927B true CN104876927B (zh) 2017-06-23

Family

ID=42677657

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201510165051.4A Active CN104876927B (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN201910261444.3A Active CN109897038B (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN201080023068.1A Active CN102448959B (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN201510215766.6A Pending CN104906100A (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN201910270919.5A Pending CN109966294A (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201910261444.3A Active CN109897038B (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN201080023068.1A Active CN102448959B (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN201510215766.6A Pending CN104906100A (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN201910270919.5A Pending CN109966294A (zh) 2009-05-26 2010-05-26 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂

Country Status (43)

Country Link
US (1) US8580794B2 (cg-RX-API-DMAC7.html)
EP (4) EP4474383A3 (cg-RX-API-DMAC7.html)
JP (8) JP5747025B2 (cg-RX-API-DMAC7.html)
KR (8) KR20170037683A (cg-RX-API-DMAC7.html)
CN (5) CN104876927B (cg-RX-API-DMAC7.html)
AR (2) AR076705A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010254160C1 (cg-RX-API-DMAC7.html)
BR (2) BR122019016429B1 (cg-RX-API-DMAC7.html)
CA (4) CA2929347A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011002949A1 (cg-RX-API-DMAC7.html)
CO (1) CO6480950A2 (cg-RX-API-DMAC7.html)
CR (2) CR20170019A (cg-RX-API-DMAC7.html)
CY (2) CY1117423T1 (cg-RX-API-DMAC7.html)
DK (1) DK2435432T6 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000367A (cg-RX-API-DMAC7.html)
EC (1) ECSP11011554A (cg-RX-API-DMAC7.html)
ES (1) ES2546294T7 (cg-RX-API-DMAC7.html)
FI (1) FI2435432T6 (cg-RX-API-DMAC7.html)
HK (1) HK1215576A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20151001T4 (cg-RX-API-DMAC7.html)
HU (2) HUE027698T2 (cg-RX-API-DMAC7.html)
IL (6) IL319747A (cg-RX-API-DMAC7.html)
LT (1) LTC2435432I2 (cg-RX-API-DMAC7.html)
ME (1) ME02205B (cg-RX-API-DMAC7.html)
MX (2) MX339469B (cg-RX-API-DMAC7.html)
MY (1) MY155645A (cg-RX-API-DMAC7.html)
NL (1) NL300873I2 (cg-RX-API-DMAC7.html)
NO (1) NO2017023I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ595708A (cg-RX-API-DMAC7.html)
PE (1) PE20120345A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500297B1 (cg-RX-API-DMAC7.html)
PL (1) PL2435432T6 (cg-RX-API-DMAC7.html)
PT (1) PT2435432E (cg-RX-API-DMAC7.html)
RS (1) RS54234B2 (cg-RX-API-DMAC7.html)
RU (3) RU2573832C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201704742YA (cg-RX-API-DMAC7.html)
SI (1) SI2435432T2 (cg-RX-API-DMAC7.html)
SM (1) SMT201500225B (cg-RX-API-DMAC7.html)
TW (3) TWI537269B (cg-RX-API-DMAC7.html)
UA (1) UA106079C2 (cg-RX-API-DMAC7.html)
UY (3) UY32668A (cg-RX-API-DMAC7.html)
WO (1) WO2010138588A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201108616B (cg-RX-API-DMAC7.html)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN106008322B (zh) * 2008-12-05 2018-09-04 Abbvie 公司 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
MX2011007681A (es) * 2009-01-19 2011-08-08 Abbott Lab Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX339469B (es) 2009-05-26 2016-05-27 Abbvie Bahamas Ltd Agentes inductores de apotosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes.
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
EP2575818A4 (en) 2010-06-03 2013-11-06 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK)
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
SG10201801794WA (en) * 2010-10-29 2018-04-27 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
NZ610151A (en) 2010-11-23 2015-06-26 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
PH12013501006A1 (en) 2010-11-23 2022-03-30 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
CN103380110A (zh) 2011-02-15 2013-10-30 宇部兴产株式会社 生产芳基硫五氟化物的工业方法
CN102241649A (zh) * 2011-07-08 2011-11-16 陈飞 3-四氢呋喃甲醇的制备方法
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013185202A1 (en) * 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
EP2882439B1 (en) * 2012-08-13 2018-04-11 AbbVie Inc. Apoptosis-inducing agents
EP3919079A1 (en) 2012-09-07 2021-12-08 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
US20150283142A1 (en) * 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
MX375194B (es) * 2012-11-01 2025-03-06 Infinity Pharmaceuticals Inc Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
AR095265A1 (es) 2013-03-13 2015-09-30 Abbvie Inc Procesos para la preparación de un agente inductor de la apoptosis
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX369503B (es) * 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
TWI594975B (zh) 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
CN106456699B (zh) 2014-05-05 2021-07-02 生物风险投资有限责任公司 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
WO2016014625A1 (en) 2014-07-22 2016-01-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells
CN104163798A (zh) * 2014-07-29 2014-11-26 苏州康润医药有限公司 3-氨基-8-三氟甲基喹啉的合成方法
ES2900184T3 (es) 2014-08-11 2022-03-16 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
CN112279808B (zh) 2014-10-06 2024-03-08 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
HRP20191019T1 (hr) 2015-07-07 2019-09-06 F. Hoffmann - La Roche Ag Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2
WO2017063572A1 (zh) * 2015-10-13 2017-04-20 苏州晶云药物科技有限公司 细胞凋亡诱导剂的新晶型及其制备方法
EP3383396B1 (en) 2015-12-04 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
WO2017156398A1 (en) 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
KR102511028B1 (ko) 2016-03-15 2023-03-16 오리존 지노믹스 에스.에이. 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물
JP7158023B2 (ja) 2016-03-15 2022-10-21 オリソン ヘノミクス エセ． アー． 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ
EP3442584B1 (en) 2016-03-15 2021-07-28 Seagen Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
EP3445452A4 (en) 2016-04-21 2019-10-30 BioVentures, LLC COMPOUNDS FOR INDUCING THE DEGRADATION OF ANTIAPOPTOTIC PROTEINS OF THE BCL-2 FAMILY AND USES THEREOF
EP4129999A1 (en) * 2016-08-05 2023-02-08 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
CN109641897B (zh) * 2016-09-01 2021-12-07 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
HUE056716T2 (hu) 2016-09-30 2022-03-28 Vertex Pharma Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására
CN106749233B (zh) * 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
EP3565815B1 (en) * 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
WO2018167652A1 (en) * 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
EP4119560B1 (en) * 2017-04-18 2024-06-05 Fochon Pharmaceuticals, Ltd. Apoptosis-inducing agents
CN107089981A (zh) * 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
CN108658983B (zh) * 2017-06-26 2019-12-20 深圳市塔吉瑞生物医药有限公司 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019020610A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag POLYTHERAPY USING BET INHIBITOR AND BCL-2 INHIBITOR
CN110869391A (zh) 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
CA3073446A1 (en) 2017-08-23 2019-02-28 Newave Pharmaceutical Inc. Bcl-2 inhibitors
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
KR102751751B1 (ko) 2018-01-10 2025-01-10 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
CA3088253A1 (en) 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MX2020008569A (es) 2018-02-16 2020-09-21 Abbvie Inc Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer.
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
CN114369094B (zh) * 2018-03-30 2023-09-29 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
LT3788042T (lt) * 2018-04-29 2025-03-25 Beigene Switzerland Gmbh Bcl-2 inhibitoriai
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
WO2019221755A1 (en) 2018-05-18 2019-11-21 Bioventures, Llc Piperlongumine analogues and uses thereof
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
TW202023568A (zh) 2018-07-30 2020-07-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
UA126098C2 (uk) 2018-07-31 2022-08-10 Есентейдж Фарма (Сучжоу) Ко., Лтд. КОМБІНОВАНИЙ ПРОДУКТ НА ОСНОВІ ІНГІБІТОРА Bcl-2 ТА ІНГІБІТОРА MDM2 ТА ЙОГО ЗАСТОСУВАННЯ В ПОПЕРЕДЖЕННІ ТА/АБО ЛІКУВАННІ ЗАХВОРЮВАНЬ
AU2019314819A1 (en) 2018-07-31 2020-10-22 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CA3092753C (en) 2018-07-31 2023-10-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab
WO2020041406A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
MX2021004856A (es) * 2018-10-29 2021-10-13 Chia Tai Tianqing Pharmaceutical Group Co Ltd Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2.
CN109320516A (zh) * 2018-11-30 2019-02-12 重庆三圣实业股份有限公司 一种维奈妥拉中间体的制备方法及其产品
CN109438441A (zh) * 2018-11-30 2019-03-08 重庆三圣实业股份有限公司 一种维奈妥拉的制备方法及其产品
WO2020232214A1 (en) 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
EP3978494A4 (en) * 2019-05-24 2023-04-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. METHYL AND TRFLUOROMETHYL CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITORS
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
WO2021037933A1 (en) 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
CN112661751B (zh) * 2019-10-16 2024-06-14 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
WO2021083135A1 (en) * 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
EP4136084A4 (en) 2020-04-15 2023-11-01 BeiGene, Ltd. BCL-2 INHIBITOR
CN115397825B (zh) * 2020-04-29 2025-09-09 正大天晴药业集团股份有限公司 三氟甲基和氯双取代的磺酰胺类选择性bcl-2抑制剂的晶体
CN111848607B (zh) * 2020-07-22 2023-03-17 长沙创新药物工业技术研究院有限公司 一种新型bcl-2/bcl-xl抑制剂、药物组合物及用途
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN114073703B (zh) * 2020-08-21 2022-12-30 苏州亚盛药业有限公司 用于治疗非酒精性脂肪肝炎的组合物和方法
WO2022089463A1 (zh) * 2020-10-28 2022-05-05 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
CN114736203A (zh) * 2021-01-07 2022-07-12 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN117642157A (zh) 2021-03-19 2024-03-01 伊尔治疗学股份有限公司 具有((3-硝基苯基)磺酰基)乙酰胺作为bcl-2抑制剂的化合物
US20240239792A1 (en) * 2021-04-13 2024-07-18 Appicine Therapeutics (Hk) Limited Modulators of bcl-2 or bcl-2/bcl-xl and uses thereof
WO2022253313A1 (zh) 2021-06-04 2022-12-08 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物的磷酸酯
EP4396180A4 (en) * 2021-08-31 2025-07-09 Beigene Ltd SOLID FORMS OF BCL-2 INHIBITORS, PROCESS FOR THEIR PREPARATION AND USE THEREOF
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
WO2023107606A1 (en) 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2024012557A1 (en) * 2022-07-15 2024-01-18 Berrybio (Hong Kong) Limited Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
JP2025525609A (ja) * 2022-07-21 2025-08-05 ベイジーン スイッツァランド ゲーエムベーハー Ｂｃｌ－２阻害剤を使用する多発性骨髄腫の治療方法
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
KR102598137B1 (ko) 2022-11-24 2023-11-06 율촌화학 주식회사 고차단성 생분해 필름 및 이의 제조방법
EP4421075A1 (en) 2023-02-27 2024-08-28 KRKA, d.d., Novo mesto Process for the preparation of venetoclax and intermediates used therein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1906183A (zh) * 2003-11-13 2007-01-31 艾博特公司 N－酰基磺酰胺细胞程序死亡促进剂
CN101534904A (zh) * 2006-09-05 2009-09-16 艾博特公司 治疗血小板过量的bcl抑制剂

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
CA2016710A1 (en) * 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
GB9110625D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
EP0672031B1 (en) * 1992-12-02 2003-03-12 Pfizer Inc. Catechol diethers as selective pde iv inhibitors
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
JPH11512429A (ja) 1995-09-15 1999-10-26 ファルマシア・アンド・アップジョン・カンパニー アミノアリールオキサゾリジノン ｎ−オキシド
JP3409029B2 (ja) * 1997-10-03 2003-05-19 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害剤としてのアリールチオフェン誘導体
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
NZ508118A (en) * 1998-07-06 2003-07-25 Bristol Myers Squibb Co Heteroaryl substituted biphenyl sulfonamides useful as dual angiotensin endothelin receptor antogonists
DE19830430A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
CA2395772C (en) * 1999-12-28 2010-09-28 Eisai Co., Ltd. Sulfonamide-containing heterocyclic compounds
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US6720338B2 (en) * 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AR031130A1 (es) * 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2446719A1 (en) 2001-06-06 2002-12-12 Eli Lilly And Company Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
US20030059489A1 (en) 2001-09-24 2003-03-27 Canolio Inc. Genital lubricating compositions and uses thereof
WO2003026587A2 (en) * 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
US6995787B2 (en) 2002-08-21 2006-02-07 Adams Steven L Sports projectile and camera apparatus
JP4336678B2 (ja) 2003-09-04 2009-09-30 株式会社日立超エル・エス・アイ・システムズ 半導体装置
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) * 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
US7851637B2 (en) * 2004-06-17 2010-12-14 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
CN101175738B (zh) * 2005-05-12 2010-10-27 雅培制药有限公司 细胞凋亡促进剂
WO2006124863A2 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
BRPI0611863B1 (pt) * 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20070115787A1 (en) * 2005-11-23 2007-05-24 Seagate Technology Llc Planar optical device for generating optical nanojets
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008064116A2 (en) * 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
ES2525229T3 (es) 2007-02-15 2014-12-19 F. Hoffmann-La Roche Ag 2-aminooxazolinas como ligandos de TAAR1
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
KR20100012031A (ko) 2007-04-19 2010-02-04 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) * 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) * 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CN106008322B (zh) * 2008-12-05 2018-09-04 Abbvie 公司 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
US8586754B2 (en) * 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010077740A2 (en) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
US20120094963A1 (en) 2008-12-23 2012-04-19 of Queen Elizabeth near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
MX2011007681A (es) 2009-01-19 2011-08-08 Abbott Lab Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes.
RU2538965C2 (ru) * 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
MX339469B (es) * 2009-05-26 2016-05-27 Abbvie Bahamas Ltd Agentes inductores de apotosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes.
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1906183A (zh) * 2003-11-13 2007-01-31 艾博特公司 N－酰基磺酰胺细胞程序死亡促进剂
CN101534904A (zh) * 2006-09-05 2009-09-16 艾博特公司 治疗血小板过量的bcl抑制剂

Also Published As

Publication number Publication date
IL253891A0 (en) 2017-10-31
CN109897038A (zh) 2019-06-18
MX2019012154A (es) 2019-11-21
CR20170019A (es) 2017-05-12
BRPI1014359A2 (pt) 2016-04-05
JP6353506B2 (ja) 2018-07-04
CL2011002949A1 (es) 2012-05-25
KR20170037683A (ko) 2017-04-04
HRP20151001T4 (hr) 2024-02-16
HK1215576A1 (en) 2016-09-02
ES2546294T3 (es) 2015-09-22
KR20180049164A (ko) 2018-05-10
RU2535347C2 (ru) 2014-12-10
JP2020023545A (ja) 2020-02-13
RU2014132884A (ru) 2015-12-27
NL300873I2 (nl) 2017-10-24
UY33047A (es) 2011-09-30
CY2017019I2 (el) 2018-01-10
JP2025072583A (ja) 2025-05-09
AU2010254160C1 (en) 2023-07-06
LTC2435432I2 (lt) 2018-06-11
CA2929347A1 (en) 2010-12-02
CA2759182A1 (en) 2010-12-02
HRP20151001T1 (hr) 2015-10-23
SG175253A1 (en) 2011-11-28
IL215644A0 (en) 2012-01-31
EP2944638A1 (en) 2015-11-18
CN104876927A (zh) 2015-09-02
DK2435432T6 (da) 2023-12-18
PH12015500297B1 (en) 2023-10-20
RS54234B2 (sr) 2024-02-29
DOP2011000367A (es) 2017-07-31
ECSP11011554A (es) 2012-01-31
KR20120034671A (ko) 2012-04-12
KR20180124164A (ko) 2018-11-20
JP2017048219A (ja) 2017-03-09
JP2015110605A (ja) 2015-06-18
NO2017023I2 (no) 2017-05-29
UA106079C2 (uk) 2014-07-25
JP2022033939A (ja) 2022-03-02
JP2018138577A (ja) 2018-09-06
ME02205B (me) 2016-02-20
RU2015154494A (ru) 2017-06-22
CN104906100A (zh) 2015-09-16
BRPI1014359B1 (pt) 2019-11-05
CR20110632A (es) 2012-02-15
AR076705A1 (es) 2011-06-29
IL269092A (en) 2019-11-28
CN109897038B (zh) 2022-04-05
PL2435432T6 (pl) 2024-02-12
EP4474383A3 (en) 2025-02-19
KR101659583B1 (ko) 2016-09-29
US20110124628A1 (en) 2011-05-26
KR20190086591A (ko) 2019-07-22
CA2759182C (en) 2016-06-07
TW201107323A (en) 2011-03-01
TWI476195B (zh) 2015-03-11
MX339469B (es) 2016-05-27
EP3656771A1 (en) 2020-05-27
US8580794B2 (en) 2013-11-12
WO2010138588A2 (en) 2010-12-02
AR109974A2 (es) 2019-02-13
CA3206963A1 (en) 2010-12-02
EP2435432B1 (en) 2015-06-24
LTPA2017015I1 (lt) 2017-06-12
TW201506025A (zh) 2015-02-16
PE20120345A1 (es) 2012-05-17
KR101723378B1 (ko) 2017-04-06
SI2435432T1 (sl) 2015-10-30
SI2435432T2 (sl) 2024-04-30
PT2435432E (pt) 2015-10-13
CO6480950A2 (es) 2012-07-16
EP2435432B3 (en) 2023-10-25
RU2628885C2 (ru) 2017-08-22
UY32668A (es) 2010-12-31
CA3052016A1 (en) 2010-12-02
JP2012528178A (ja) 2012-11-12
RS54234B1 (sr) 2015-12-31
NO2017023I1 (no) 2017-05-29
ZA201108616B (en) 2015-12-23
MY155645A (en) 2015-11-13
JP5747025B2 (ja) 2015-07-08
WO2010138588A3 (en) 2011-04-07
MX2011012257A (es) 2011-12-16
ES2546294T7 (es) 2024-06-06
PL2435432T3 (pl) 2015-12-31
IL286036A (en) 2021-10-31
UY37825A (es) 2020-02-28
FI2435432T6 (fi) 2023-11-21
IL215644A (en) 2017-08-31
RU2535347C3 (ru) 2019-05-14
TW201607946A (zh) 2016-03-01
HK1163099A1 (en) 2012-09-07
IL319747A (en) 2025-05-01
DK2435432T3 (en) 2015-08-31
KR102001418B1 (ko) 2019-07-19
JP2023040165A (ja) 2023-03-22
PH12015500297A1 (en) 2015-12-07
CN102448959B (zh) 2015-06-17
RU2011152973A (ru) 2013-07-10
AU2010254160A1 (en) 2011-11-24
SMT201500225B (it) 2015-10-30
JP6038195B2 (ja) 2016-12-07
AU2010254160B2 (en) 2015-02-12
CY2017019I1 (el) 2018-01-10
KR20230128571A (ko) 2023-09-05
SG10201704742YA (en) 2017-07-28
WO2010138588A9 (en) 2011-05-05
EP2435432A2 (en) 2012-04-04
HUS1700021I1 (hu) 2017-06-28
CN109966294A (zh) 2019-07-05
TWI561523B (en) 2016-12-11
CY1117423T1 (el) 2017-04-26
HUE027698T2 (en) 2016-10-28
TWI537269B (zh) 2016-06-11
RU2573832C2 (ru) 2016-01-27
IL299019A (en) 2023-02-01
EP4474383A2 (en) 2024-12-11
CN102448959A (zh) 2012-05-09
BR122019016429B1 (pt) 2020-03-24
KR20190130676A (ko) 2019-11-22
KR20150065947A (ko) 2015-06-15
NZ595708A (en) 2014-03-28
KR101920202B1 (ko) 2018-11-21

Similar Documents

Publication Publication Date Title
CN104876927B (zh) 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN103153993B (zh) 治疗癌症和免疫与自身免疫疾病的细胞程序死亡诱导药剂
US20130267514A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US11897864B2 (en) Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2015202183B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20170525

Address after: Bermuda Hamilton

Applicant after: Aibo Wei Ireland Ltd.

Address before: Bahamas Nassau

Applicant before: ABBOTT LABAORATORIES

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant